JAK2 and erythroleukemia: To functionally assess the contribution of high DUSP1 expression in the JAK2V617F+ progenitors, we used human erythroleukemia (HEL) cells harboring the V617F oncogenic mutation as well as CRISPR/Cas9 JAK2-edited (JAK2wt) HEL cells (see Supplementary Materials and Methods for details on JAK2-edited HEL cells) and exposed them to a DUSP1/6 inhibitor ((E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one; BCI) [52].